NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Short Interest Drops 91.8%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 38,236 shares, a decrease of 91.8% from the August 31st total of 469,120 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average daily volume of 40,192 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NRSN. HC Wainwright started coverage on shares of NeuroSense Therapeutics in a research report on Thursday, September 3rd. They set a “buy” rating for the company. Weiss Ratings lowered shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.00.

Institutional Investors Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $77,000. NeuroSense Therapeutics makes up about 0.0% of Yorkville Advisors Global LP’s holdings, making the stock its 24th biggest position. Yorkville Advisors Global LP owned approximately 0.73% of NeuroSense Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ:NRSN remained flat at $7.40 during midday trading on Thursday. The company had a trading volume of 8,880 shares, compared to its average volume of 25,171. NeuroSense Therapeutics has a 12 month low of $5.00 and a 12 month high of $26.64. The company has a market capitalization of $14.06 million, a price-to-earnings ratio of -0.69 and a beta of 1.60. The business’s 50 day moving average price is $9.06 and its two-hundred day moving average price is $13.20.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.